Last Update 20 Apr 26

VIR: Oncology Collaboration And Prostate Cancer Data Will Support Future Upside

Analysts have generally lifted their price targets on Vir Biotechnology into a $17 to $30 range, citing the Astellas collaboration, early VIR-5500 oncology data, and progress in hepatitis D as key reasons for the higher valuations.

Analyst Commentary

Recent Street research skews clearly positive on Vir Biotechnology, with several firms lifting price targets into the high teens to low thirties after reviewing oncology and hepatitis D updates and the Astellas partnership.

Bullish Takeaways

Bullish analysts point to the Astellas collaboration, including US$335m in upfront and near term payments plus a 50/50 U.S. profit split and ex U.S. royalties, as a key support for Vir’s valuation and funding for its bispecific and oncology pipeline.
Multiple research notes highlight VIR-5500 Phase 1 and Phase 1b data in prostate cancer as compelling, with some calling the profile potentially best in class and viewing the asset as a leader among PSMA targeted T cell engagers. This in turn feeds into higher expectations for the oncology franchise.
Commentary describing the Astellas deal as a big win for the bispecific pipeline, combined with better than expected Q4 results and full ASCO GU data, has led bullish analysts to frame Vir as a differentiated oncology company with a broader growth runway than previously assumed.
Several firms say Vir appears well capitalized to execute across its dual franchises in oncology and infectious disease. This reinforces confidence that the company can advance programs like hepatitis D and VIR-5500 without needing to rely on near term equity issuance.

Bearish Takeaways

Some cautious analysts still appear to be calibrating expectations around clinical execution risk in prostate cancer and hepatitis D, even as they lift price targets. This suggests that a portion of the upside case is tied to successful data readouts and regulatory outcomes that remain unproven.
References to probability of success assumptions and peak market share estimates in prostate cancer underline that valuation work relies on modeled scenarios, not realized commercial performance. Readers should recognize that these inputs can change if future data are less favorable.
One prior Barclays report, which reduced its target before more recent increases, signals that sentiment can swing with new information on clinical data timing, comparative profiles and deal terms. This reminds investors that Street enthusiasm is conditional rather than uniformly firm.
Even with upgrades and higher price targets, not all research is framed as a strong buy case. This indicates that some on the Street still see a balance between upside from oncology and partnership news and the inherent uncertainty around early and mid stage drug development.

What's in the News

Vir Biotechnology closed its global collaboration and licensing agreement with Astellas for VIR-5500 following expiration of the Hart Scott Rodino waiting period, receiving a US$240m upfront payment, a US$75m equity investment at US$10.36 per share, and a near term US$20m milestone, with potential for up to US$1.37b in additional milestones and tiered double digit ex U.S. royalties, while sharing certain proceeds with Sanofi (Client Announcements).
The first patient was dosed in a monotherapy expansion cohort of the Phase 1 trial for VIR-5500 in late line metastatic castration resistant prostate cancer, using a step up dosing regimen and focusing on safety and efficacy measures such as PSA response rate and Objective Response Rate, with combination cohorts planned in early line mCRPC and mHSPC (Product Related Announcements).
New Phase 1 data for VIR-5500 in advanced mCRPC indicated that monotherapy was well tolerated with promising anti tumor activity, with results presented in an oral session at the 2026 ASCO Genitourinary Cancers Symposium and plans described for further dose expansion and potential Phase 3 trials (Product Related Announcements).
Vir Biotechnology completed a follow on equity offering of common stock totaling US$150,000,002 at US$8.50 per share for 17,647,059 shares, following a filed offering size of US$200m (Follow on Equity Offerings).
Certain common stock, restricted stock units, and stock options are subject to a lock up agreement running from February 25, 2026 to April 27, 2026, limiting disposals or hedging by the company, directors, and executive officers without underwriter consent during this period (End of Lock Up Period).

Valuation Changes

Fair Value: $20.78 is unchanged in the latest update, suggesting no revision to the overall intrinsic value estimate.
Discount Rate: 7.18% to 7.24%, risen slightly, which can modestly lower the present value of projected cash flows.
Revenue Growth: 27.44% to 27.44%, effectively steady, indicating no material change to long term top line growth assumptions.
Net Profit Margin: 14.76% to 14.82%, risen slightly, implying a small improvement in expected long term profitability.
Future P/E: 174.76x to 174.24x, edged down, reflecting a marginally lower multiple applied to projected earnings.

5 views

Key Takeaways

ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams.
Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.
Reliance on unproven therapies and regulatory hurdles poses risks to market position, revenues, and financial performance despite cost-cutting efforts and partnership needs.

Catalysts

About Vir Biotechnology

A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Vir Biotechnology's ECLIPSE Phase III program in hepatitis delta, which aims to become the new standard of care given the significant unmet medical need and regulatory designations, is expected to potentially drive revenue growth.
The strong foundational patent rights to the PRO-XTEN platform enable expansion into additional high-value oncology indications, potentially increasing earnings through diversification and broadening revenue streams.
Significant progress has been made in oncology with promising T-cell engager therapies for colorectal and prostate cancers, suggesting future revenue increases from novel oncology treatments.
Financial restructuring efforts, leading to a significant reduction in operating expenses and cash burn, are set to improve net margins, thereby enhancing long-term financial health and value creation.
The cash runway extending into mid-2027 and disciplined capital allocation ensure the capability to sustain key clinical development programs, thereby supporting future earnings growth.

Vir Biotechnology Earnings and Revenue Growth

Vir Biotechnology Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Vir Biotechnology's revenue will grow by 27.4% annually over the next 3 years.
Analysts are not forecasting that Vir Biotechnology will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Vir Biotechnology's profit margin will increase from -638.9% to the average US Biotechs industry of 14.8% in 3 years.
If Vir Biotechnology's profit margin were to converge on the industry average, you could expect earnings to reach $21.0 million (and earnings per share of $0.15) by about April 2029, up from -$438.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 174.8x on those 2029 earnings, up from -3.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.1x.
Analysts expect the number of shares outstanding to grow by 0.93% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant uncertainties and risks are associated with forward-looking statements, which could impact the company's future earnings if clinical development programs do not meet projected outcomes.
Reliance on unproven novel therapies and the early stage of oncology programs could lead to variability in clinical trial success, posing risks to revenue generation and market positioning.
The need for commercialization and development partners, particularly for the hepatitis B program, suggests potential challenges in scaling operations, which could affect net margins if partnerships are not secured.
Substantial R&D expenses and net losses, despite cost-cutting efforts, may continue to strain financial performance and cash flow if product commercialization timelines are delayed.
Dependence on regulatory approvals and the proposal of new therapies impacting revenues, as failure to get regulatory endorsements could affect expected market gains and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $20.78 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $17.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $141.9 million, earnings will come to $21.0 million, and it would be trading on a PE ratio of 174.8x, assuming you use a discount rate of 7.2%.
Given the current share price of $10.75, the analyst price target of $20.78 is 48.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Vir Biotechnology?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success